Literature DB >> 26008752

Immunoliposome-mediated drug delivery to Plasmodium-infected and non-infected red blood cells as a dual therapeutic/prophylactic antimalarial strategy.

Ernest Moles1, Patricia Urbán1, María Belén Jiménez-Díaz2, Sara Viera-Morilla2, Iñigo Angulo-Barturen2, Maria Antònia Busquets3, Xavier Fernàndez-Busquets4.   

Abstract

One of the most important factors behind resistance evolution in malaria is the failure to deliver sufficiently high amounts of drugs to early stages of Plasmodium-infected red blood cells (pRBCs). Despite having been considered for decades as a promising approach, the delivery of antimalarials encapsulated in immunoliposomes targeted to pRBCs has not progressed towards clinical applications, whereas in vitro assays rarely reach drug efficacy improvements above 10-fold. Here we show that encapsulation efficiencies reaching >96% are achieved for the weak basic drugs chloroquine (CQ) and primaquine using the pH gradient loading method in liposomes containing neutral saturated phospholipids. Targeting antibodies are best conjugated through their primary amino groups, adjusting chemical crosslinker concentration to retain significant antigen recognition. Antigens from non-parasitized RBCs have also been considered as targets for the delivery to the cell of drugs not affecting the erythrocytic metabolism. Using this strategy, we have achieved unprecedented complete nanocarrier targeting to early intraerythrocytic stages of the malaria parasite for which there is a lack of specific extracellular molecular tags. Immunoliposomes studded with monoclonal antibodies raised against the erythrocyte surface protein glycophorin A were capable of targeting 100% RBCs and pRBCs at the low concentration of 0.5μM total lipid in the culture, with >95% of added liposomes retained on cell surfaces. When exposed for only 15min to Plasmodium falciparum in vitro cultures of early stages, free CQ had no significant effect on the viability of the parasite up to 200nM, whereas immunoliposomal 50nM CQ completely arrested its growth. In vivo assays in mice showed that immunoliposomes cleared the pathogen below detectable levels at a CQ dose of 0.5mg/kg, whereas free CQ administered at 1.75mg/kg was, at most, 40-fold less efficient. Our data suggest that this significant improvement is in part due to a prophylactic effect of CQ found by the pathogen in its host cell right at the very moment of invasion.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Chloroquine (PubChem CID: 2719); Cholesterol (PubChem CID: 5997); DOPC (PubChem CID: 6437081); DSPC (PubChem CID: 94190); Hoechst 33342 (PubChem CID: 1464); Immunoliposomes; Malaria; Maleimide (PubChem CID: 10935); Nanomedicine; Plasmodium; Primaquine (PubChem CID: 4908); Pyranine (PubChem CID: 61389); SATA (PubChem CID: 127532); Targeted drug delivery

Mesh:

Substances:

Year:  2015        PMID: 26008752     DOI: 10.1016/j.jconrel.2015.05.284

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  16 in total

1.  Antiplasmodial activity of targeted zinc(II)-dipicolylamine complexes.

Authors:  Douglas R Rice; María de Lourdes Betancourt Mendiola; Claribel Murillo-Solano; Lisa A Checkley; Michael T Ferdig; Juan C Pizarro; Bradley D Smith
Journal:  Bioorg Med Chem       Date:  2017-03-27       Impact factor: 3.641

Review 2.  Red blood cells: The metamorphosis of a neglected carrier into the natural mothership for artificial nanocarriers.

Authors:  Patrick M Glassman; Elizabeth D Hood; Laura T Ferguson; Zongmin Zhao; Don L Siegel; Samir Mitragotri; Jacob S Brenner; Vladimir R Muzykantov
Journal:  Adv Drug Deliv Rev       Date:  2021-09-29       Impact factor: 15.470

3.  Detection of Protein Aggregation in Live Plasmodium Parasites.

Authors:  Arnau Biosca; Inés Bouzón-Arnáiz; Lefteris Spanos; Inga Siden-Kiamos; Valentín Iglesias; Salvador Ventura; Xavier Fernàndez-Busquets
Journal:  Antimicrob Agents Chemother       Date:  2020-05-21       Impact factor: 5.191

Review 4.  Red blood cells: Supercarriers for drugs, biologicals, and nanoparticles and inspiration for advanced delivery systems.

Authors:  Carlos H Villa; Aaron C Anselmo; Samir Mitragotri; Vladimir Muzykantov
Journal:  Adv Drug Deliv Rev       Date:  2016-03-03       Impact factor: 15.470

5.  Anti-PD-L1 mediating tumor-targeted codelivery of liposomal irinotecan/JQ1 for chemo-immunotherapy.

Authors:  Zhi-di He; Meng Zhang; Yong-Hui Wang; Yang He; Hai-Rui Wang; Bin-Fan Chen; Bin Tu; Si-Qi Zhu; Yong-Zhuo Huang
Journal:  Acta Pharmacol Sin       Date:  2020-12-11       Impact factor: 7.169

6.  Pulmonary delivery of triptolide-loaded liposomes decorated with anti-carbonic anhydrase IX antibody for lung cancer therapy.

Authors:  Congcong Lin; Blenda Chi Kwan Wong; Hubiao Chen; Zhaoxiang Bian; Ge Zhang; Xue Zhang; Muhammad Kashif Riaz; Deependra Tyagi; Ge Lin; Yanbo Zhang; Jinjin Wang; Aiping Lu; Zhijun Yang
Journal:  Sci Rep       Date:  2017-04-20       Impact factor: 4.379

7.  Adaptation of targeted nanocarriers to changing requirements in antimalarial drug delivery.

Authors:  Joana Marques; Juan José Valle-Delgado; Patricia Urbán; Elisabet Baró; Rafel Prohens; Alfredo Mayor; Pau Cisteró; Michael Delves; Robert E Sinden; Christian Grandfils; José L de Paz; José A García-Salcedo; Xavier Fernàndez-Busquets
Journal:  Nanomedicine       Date:  2016-10-05       Impact factor: 5.307

8.  Evidence of Protein Adsorption in Pegylated Liposomes: Influence of Liposomal Decoration.

Authors:  Marc Sangrà; Joan Estelrich; Raimon Sabaté; Alba Espargaró; Maria Antònia Busquets
Journal:  Nanomaterials (Basel)       Date:  2017-02-10       Impact factor: 5.076

9.  Modeling the Distribution of Diprotic Basic Drugs in Liposomal Systems: Perspectives on Malaria Nanotherapy.

Authors:  Ernest Moles; Maria Kavallaris; Xavier Fernàndez-Busquets
Journal:  Front Pharmacol       Date:  2019-09-25       Impact factor: 5.810

Review 10.  Nanomedicine Reformulation of Chloroquine and Hydroxychloroquine.

Authors:  David M Stevens; Rachael M Crist; Stephan T Stern
Journal:  Molecules       Date:  2020-12-31       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.